Effect of aspirin dose on mortality and cardiovascular events in people with diabetes: A meta-analysis

Journal of General Internal Medicine

Volumn 26, Issue 11, 2011, Pages 1336-1344

  Simpson, Scot H ^a   Gamble, John Michael ^a   Mereu, Laurie ^a   Chambers, Thane ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

aspirin; diabetes; mortality; myocardial infarction; stroke

Indexed keywords

ACETYLSALICYLIC ACID;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COHORT ANALYSIS; DIABETIC PATIENT; DOSE RESPONSE; DRUG EFFICACY; FOLLOW UP; HEART INFARCTION; HEART INFARCTION PREVENTION; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; META ANALYSIS; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIMARY PREVENTION; REVIEW; SECONDARY PREVENTION; STROKE; TREATMENT OUTCOME;

ASPIRIN; CARDIOVASCULAR DISEASES; DIABETES MELLITUS; HUMANS; PLATELET AGGREGATION INHIBITORS; PRIMARY PREVENTION; STROKE;

EID: 80755153633     PISSN: 08848734     EISSN: 15251497     Source Type: Journal    
DOI: 10.1007/s11606-011-1757-y     Document Type: Review

References (55)

1. Canadian Diabetes Association Clinical Practice Guidelines Expert Committee 2008 Vascular protection in people with diabetes Can J Diabetes 32 suppl 1 S102 S106
2. JB Buse HN Ginsberg GL Bakris, et al. 2007 Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association Diabetes Care 30 1 162 172 17192355 10.2337/dc07-9917 1:CAS:528: DC%2BD2sXhsFWqur8%3D (Pubitemid 46052519)
3. L Ryden E Standl M Bartnik, et al. 2007 Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD) Eur Heart J 28 1 88 136 17220161 10.1093/eurheartj/ehm124 1:CAS:528:DC%2BD2sXitlaiur8%3D (Pubitemid 47355991)
4. Collaborative overview of randomised trials of antiplatelet therapy - I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration. BMJ 1994;308(6921):81-106.
5. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324(7329):71-86.
6. Final report on the aspirin component of the ongoing Physicians' Health Study. Steering Committee of the Physicians' Health Study Research Group. N Engl J Med 1989;321(3):129-135.
7. L Hansson A Zanchetti SG Carruthers, et al. 1998 Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group Lancet 351 9118 1755 1762 9635947 10.1016/S0140-6736(98)04311-6 1:CAS:528:DyaK1cXksV2qtrY%3D (Pubitemid 28269185)
8. M Sacco F Pellegrini MC Roncaglioni F Avanzini G Tognoni A Nicolucci 2003 Primary Prevention of Cardiovascular Events With Low-Dose Aspirin and Vitamin E in Type 2 Diabetic Patients: Results of the Primary Prevention Project (PPP) trial Diabetes Care 26 12 3264 3272 14633812 10.2337/diacare.26.12.3264 1:CAS:528:DC%2BD3sXpvF2ks7Y%3D (Pubitemid 37466885)
9. Aspirin effects on mortality and morbidity in patients with diabetes mellitus. Early Treatment Diabetic Retinopathy Study report 14. ETDRS Investigators. JAMA 1992;268(10):1292-1300.
10. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001;285(19):2486-2497.
11. H Ogawa M Nakayama T Morimoto, et al. 2008 Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial JAMA 300 18 2134 2141 18997198 10.1001/jama.2008.623 1:CAS:528:DC%2BD1cXhtlOrtLnM
12. J Belch A MacCuish I Campbell, et al. 2008 The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease BMJ 337 a1840 18927173 10.1136/bmj.a1840
13. L Welin L Wilhelmsen A Bjornberg A Oden 2009 Aspirin increases mortality in diabetic patients without cardiovascular disease: a Swedish record linkage study Pharmacoepidemiol Drug Saf 18 12 1143 1149 19672841 10.1002/pds.1828
14. WY Leung WY So D Stewart, et al. 2009 Lack of benefits for prevention of cardiovascular disease with aspirin therapy in type 2 diabetic patients-a longitudinal observational study Cardiovascular Diabetology 8 57 19878541 10.1186/1475-2840-8-57
15. JA Colwell 2009 Does aspirin use reduce cardiovascular risk in diabetes? Nat Rev Endocrinol 5 4 188 190 19352314 10.1038/nrendo.2009.44
16. M Pignone MJ Alberts JA Colwell, et al. 2010 Aspirin for primary prevention of cardiovascular events in people with diabetes Diabetes Care 33 6 1395 1402 20508233 10.2337/dc10-0555
17. G De Berardis M Sacco GF Strippoli, et al. 2009 Aspirin for primary prevention of cardiovascular events in people with diabetes: meta-analysis of randomised controlled trials BMJ 339 b4531 19897665 10.1136/bmj.b4531
18. C Baigent L Blackwell R Collins, et al. 2009 Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials Lancet 373 9678 1849 1860 19482214 10.1016/S0140-6736(09)60503-1
19. C Zhang A Sun P Zhang, et al. 2010 Aspirin for primary prevention of cardiovascular events in patients with diabetes: A meta-analysis Diabetes Res Clin Pract 87 2 211 218 19853947 10.1016/j.diabres.2009.09.029 1:CAS:528:DC%2BC3cXhtVGgu7g%3D
20. N Younis S Williams B Ammori H Soran 2010 Role of aspirin in the primary prevention of cardiovascular disease in diabetes mellitus: a meta-analysis Expert Opin Pharmacother 11 9 1459 1466 20429671 10.1517/14656561003792538 1:CAS:528:DC%2BC3cXmt12ltrY%3D
21. S Stavrakis JA Stoner M Azar S Wayangankar U Thadani 2011 Low-dose aspirin for primary prevention of cardiovascular events in patients with diabetes: a meta-analysis Am J Med Sci 341 1 1 9 21191260 10.1097/MAJ. 0b013e3181f1fba8
22. G Krasopoulos SJ Brister WS Beattie MR Buchanan 2008 Aspirin "resistance" and risk of cardiovascular morbidity: systematic review and meta-analysis BMJ 336 7637 195 198 18202034 10.1136/bmj.39430.529549.BE (Pubitemid 351212675)
23. US Tantry E Mahla PA Gurbel 2009 Aspirin resistance Prog Cardiovasc Dis 52 2 141 152 19732606 10.1016/j.pcad.2009.05.001 1:CAS:528:DC%2BD1MXht1Gnsr7K
24. R Ajjan RF Storey PJ Grant 2008 Aspirin resistance and diabetes mellitus Diabetologia 51 3 385 390 18197397 10.1007/s00125-007-0898-3 1:STN:280:DC%2BD1c%2FosVyisQ%3D%3D
25. MM Hovens JD Snoep JC Eikenboom JG van der Bom BJ Mertens MV Huisman 2007 Prevalence of persistent platelet reactivity despite use of aspirin: a systematic review Am Heart J 153 2 175 181 17239674 10.1016/j.ahj.2006.10.040 1:CAS:528:DC%2BD2sXntlGqsA%3D%3D (Pubitemid 46096871)
26. SS Mehta RJ Silver A Aaronson M Abrahamson AB Goldfine 2006 Comparison of aspirin resistance in type 1 versus type 2 diabetes mellitus Am J Cardiol 97 4 567 570 16461058 10.1016/j.amjcard.2005.09.093 1:CAS:528:DC%2BD28XhtlaqtLg%3D (Pubitemid 43190052)
27. S Fateh-Moghadam U Plockinger N Cabeza, et al. 2005 Prevalence of aspirin resistance in patients with type 2 diabetes Acta Diabetol 42 2 99 103 15944844 10.1007/s00592-005-0186-y 1:CAS:528:DC%2BD2MXkvFSqsrg%3D (Pubitemid 40881115)
28. J Dichiara KP Bliden US Tantry, et al. 2007 The effect of aspirin dosing on platelet function in diabetic and nondiabetic patients: an analysis from the aspirin-induced platelet effect (ASPECT) study Diabetes 56 12 3014 3019 17848625 10.2337/db07-0707 1:CAS:528:DC%2BD2sXhsValurvJ (Pubitemid 350223637)
29. EH Law SH Simpson 2010 Aspirin use rates in diabetes: a systematic review and cross-sectional study Can J Diabetes 34 3 211 217
30. SH Downs N Black 1998 The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions J Epidemiol Community Health 52 6 377 384 9764259 10.1136/jech.52.6.377 1:STN:280:DyaK1cvjs1Omsg%3D%3D (Pubitemid 28438523)
31. R DerSimonian N Laird 1986 Meta-analysis in clinical trials Control Clin Trials 7 3 177 188 3802833 10.1016/0197-2456(86)90046-2 1:STN:280: DyaL2s7gsVamtA%3D%3D (Pubitemid 17189972)
32. VL Serebruany AI Malinin RM Eisert DC Sane 2004 Risk of bleeding complications with antiplatelet agents: meta-analysis of 338,191 patients enrolled in 50 randomized controlled trials Am J Hematol 75 1 40 47 14695631 10.1002/ajh.10451 1:CAS:528:DC%2BD2cXhtVOntbw%3D (Pubitemid 38040166)
33. VL Serebruany SR Steinhubl PB Berger, et al. 2005 Analysis of risk of bleeding complications after different doses of aspirin in 192,036 patients enrolled in 31 randomized controlled trials Am J Cardiol 95 10 1218 1222 15877994 10.1016/j.amjcard.2005.01.049 1:CAS:528:DC%2BD2MXjvVOiur8%3D (Pubitemid 40616424)
34. WA Ray 2005 Observational studies of drugs and mortality N Engl J Med 353 22 2319 2321 16319379 10.1056/NEJMp058267 1:CAS:528:DC%2BD2MXht1OmsbrM (Pubitemid 41713742)
35. NJ Morrish SL Wang LK Stevens JH Fuller H Keen 2001 Mortality and causes of death in the WHO Multinational Study of Vascular Disease in Diabetes Diabetologia 44 Suppl 2 S14 S21 11587045 10.1007/PL00002934 (Pubitemid 32844108)
36. SP Jansson DK Andersson K Svardsudd 2010 Mortality trends in subjects with and without diabetes during 33 years of follow-up Diabetes Care 33 3 551 556 20009100 10.2337/dc09-0680
37. HC Diener L Cunha C Forbes J Sivenius P Smets A Lowenthal 1996 European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke J Neurol Sci 143 1-2 1 13 8981292 10.1016/S0022-510X(96)00308-5 1:CAS:528:DyaK2sXisFOktQ%3D%3D (Pubitemid 26402780)
38. PM Ridker NR Cook IM Lee, et al. 2005 A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women N Engl J Med 352 13 1293 1304 15753114 10.1056/NEJMoa050613 1:CAS:528: DC%2BD2MXislCjs7Y%3D (Pubitemid 40411496)
39. Swedish Aspirin Low-Dose Trial (SALT) of 75 mg aspirin as secondary prophylaxis after cerebrovascular ischaemic events. The SALT Collaborative Group. Lancet 1991;338(8779):1345-1349.
40. P Petersen G Boysen J Godtfredsen ED Andersen B Andersen 1989 Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study Lancet 1 8631 175 179 2563096 10.1016/S0140-6736(89)91200-2 1:STN:280:DyaL1M%2Fps1Wrtw%3D%3D (Pubitemid 19038801)
41. M Catalano G Born R Peto 2007 Prevention of serious vascular events by aspirin amongst patients with peripheral arterial disease: randomized, double-blind trial J Intern Med 261 3 276 284 17305650 10.1111/j.1365-2796.2006. 01763.x 1:STN:280:DC%2BD2s7gvVGjtQ%3D%3D
42. FG Fowkes JF Price MC Stewart, et al. 2010 Aspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial index: a randomized controlled trial JAMA 303 9 841 848 20197530 10.1001/jama.2010.221 1:CAS:528:DC%2BC3cXivFKrtrc%3D
43. B Farrell J Godwin S Richards C Warlow 1991 The United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: final results J Neurol Neurosurg Psychiatry 54 12 1044 1054 1783914 10.1136/jnnp.54.12.1044 1:STN:280: DyaK387kvVClsA%3D%3D
44. R Peto R Gray R Collins, et al. 1988 Randomised trial of prophylactic daily aspirin in British male doctors Br Med J (Clin Res Ed) 296 6618 313 316 10.1136/bmj.296.6618.313 1:STN:280:DyaL1c7ltVCjsA%3D%3D (Pubitemid 18042841)
45. PC Elwood PM Sweetnam 1979 Aspirin and secondary mortality after myocardial infarction Lancet 2 8156-8157 1313 1315 92668 10.1016/S0140-6736(79) 92808-3 1:CAS:528:DyaL3cXhsFOrtLk%3D (Pubitemid 10199358)
46. Aspirin in coronary heart disease 1976 The Coronary Drug Project Research Group J Chronic Dis 29 10 625 642 10.1016/0021-9681(76)90020-5
47. JA Cairns M Gent J Singer, et al. 1985 Aspirin, sulfinpyrazone, or both in unstable angina. Results of a Canadian multicenter trial N Engl J Med 313 22 1369 1375 3903504 10.1056/NEJM198511283132201 1:STN:280:DyaL28%2FktVakuw%3D%3D (Pubitemid 16211835)
48. HH Feringa JJ Bax SE Karagiannis, et al. 2009 Elderly patients undergoing major vascular surgery: risk factors and medication associated with risk reduction Arch Gerontol Geriatr 48 1 116 120 18177954 10.1016/j.archger.2007.11. 003
49. FA McAlister WA Ghali Y Gong J Fang PW Armstrong JV Tu 2006 Aspirin use and outcomes in a community-based cohort of 7352 patients discharged after first hospitalization for heart failure Circulation 113 22 2572 2578 16735672 10.1161/CIRCULATIONAHA.105.602136 (Pubitemid 43948005)
50. RM Cubbon CP Gale A Rajwani, et al. 2008 Aspirin and mortality in patients with diabetes sustaining acute coronary syndrome Diabetes Care 31 2 363 365 17959865 10.2337/dc07-1745 (Pubitemid 351213352)
51. G Ong TM Davis WA Davis 2010 Aspirin is associated with reduced cardiovascular and all-cause mortality in type 2 diabetes in a primary prevention setting: the Fremantle Diabetes study Diabetes Care 33 2 317 321 19918016 10.2337/dc09-1701 1:CAS:528:DC%2BC3cXitlaltr8%3D
52. Zanchetti A. Aspirin and Antiplatelet Drugs in the Prevention of Cardiovascular Complications of Diabetes. In: Morgensen CE, ed. Pharmacotherapy of diabetes: new developments. New York: Springer; 2007:211-218.
53. Cochrane Handbook for Systematic Reviews of Interventions. 5.0.2 [updated September 2009] ed. The Cochrane Collaboration; 2008.
54. Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. The Medical Research Council's General Practice Research Framework. Lancet 1998;351(9098):233-241.
55. PC Lambert AJ Sutton KR Abrams DR Jones 2002 A comparison of summary patient-level covariates in meta-regression with individual patient data meta-analysis J Clin Epidemiol 55 1 86 94 11781126 10.1016/S0895-4356(01)00414-0 1:STN:280:DC%2BD38%2FlsFymsw%3D%3D (Pubitemid 34037039)